GMP & T Cell Therapy Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Biosciences, University Heidelberg, Heidelberg, Germany.
Front Immunol. 2023 Jun 20;14:1199374. doi: 10.3389/fimmu.2023.1199374. eCollection 2023.
The expression of immune checkpoint molecules (ICMs) by cancer cells is known to counteract tumor-reactive immune responses, thereby promoting tumor immune escape. For example, upregulated expression of ecto-5'-nucleotidase (NT5E), also designated as CD73, increases extracellular levels of immunosuppressive adenosine, which inhibits tumor attack by activated T cells. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression at the post-transcriptional level. Thus, the binding of miRNAs to the 3'-untranslated region of target mRNAs either blocks translation or induces degradation of the targeted mRNA. Cancer cells often exhibit aberrant miRNA expression profiles; hence, tumor-derived miRNAs have been used as biomarkers for early tumor detection.
In this study, we screened a human miRNA library and identified miRNAs affecting the expression of ICMs NT5E, ENTPD1, and CD274 in the human tumor cell lines SK-Mel-28 (melanoma) and MDA-MB-231 (breast cancer). Thereby, a set of potential tumor-suppressor miRNAs that decreased ICM expression in these cell lines was defined. Notably, this study also introduces a group of potential oncogenic miRNAs that cause increased ICM expression and presents the possible underlying mechanisms. The results of high-throughput screening of miRNAs affecting NT5E expression were validated in 12 cell lines of various tumor entities.
As result, miR-1285-5p, miR-155-5p, and miR-3134 were found to be the most potent inhibitors of NT5E expression, while miR-134-3p, miR-6859-3p, miR-6514-3p, and miR-224-3p were identified as miRNAs that strongly enhanced NT5E expression levels.
The miRNAs identified might have clinical relevance as potential therapeutic agents and biomarkers or therapeutic targets, respectively.
癌细胞中免疫检查点分子(ICMs)的表达被认为会抵消肿瘤反应性免疫反应,从而促进肿瘤免疫逃逸。例如,ecto-5'-核苷酸酶(NT5E)的上调表达,也称为 CD73,增加了免疫抑制性腺苷的细胞外水平,从而抑制了激活的 T 细胞对肿瘤的攻击。微小 RNA(miRNA)是一种小的非编码 RNA,可在转录后水平调节基因表达。因此,miRNA 与靶 mRNA 的 3'-非翻译区结合,要么阻止翻译,要么诱导靶向 mRNA 的降解。癌细胞通常表现出异常的 miRNA 表达谱;因此,肿瘤衍生的 miRNA 已被用作早期肿瘤检测的生物标志物。
在这项研究中,我们筛选了人类 miRNA 文库,并鉴定了影响 SK-Mel-28(黑色素瘤)和 MDA-MB-231(乳腺癌)人类肿瘤细胞系中 ICMs NT5E、ENTPD1 和 CD274 表达的 miRNA。从而定义了一组降低这些细胞系中 ICM 表达的潜在肿瘤抑制 miRNA。值得注意的是,本研究还介绍了一组潜在的致癌 miRNA,它们导致 ICM 表达增加,并提出了可能的潜在机制。影响 NT5E 表达的 miRNA 的高通量筛选结果在 12 种不同肿瘤实体的细胞系中得到了验证。
结果发现,miR-1285-5p、miR-155-5p 和 miR-3134 是 NT5E 表达最有效的抑制剂,而 miR-134-3p、miR-6859-3p、miR-6514-3p 和 miR-224-3p 被鉴定为强烈增强 NT5E 表达水平的 miRNA。
鉴定出的 miRNA 可能具有临床相关性,分别作为潜在的治疗剂和生物标志物或治疗靶点。